Lancet 2021 Sep 20
Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial.
Abstract
Background
Novel adjuvant strategies are needed to optimise outcomes after complete surgical resection in patients with early-stage non-small-cell lung cancer (NSCLC). We aimed to evaluate adjuvant atezolizumab versus best supportive care after adjuvant platinum-based chemotherapy in these patients.
Methods
IMpower010 was a randomised, multicentre, open-label, phase 3 study done at 227 sites in 22 countries and regions. Eligible patients were 18 years or older with completely resected stage IB (tumours ≥4 cm) to IIIA NSCLC per the Union Internationale Contre le Cancer and American Joint Committee on Cancer staging system (7th edition). Patients were randomly assigned (1:1) by a permuted-block method (block size of four) to receive adjuvant atezolizumab (1200 mg every 21 days; for 16 cycles or 1 year) or best supportive care (observation and regular scans for disease recurrence) after adjuvant platinum-based chemotherapy (one to four cycles). The primary endpoint, investigator-assessed disease-free survival, was tested hierarchically first in the stage II-IIIA population subgroup whose tumours expressed PD-L1 on 1% or more of tumour cells (SP263), then all patients in the stage II-IIIA population, and finally the intention-to-treat (ITT) population (stage IB-IIIA). Safety was evaluated in all patients who were randomly assigned and received atezolizumab or best supportive care. IMpower010 is registered with ClinicalTrials.gov, NCT02486718 (active, not recruiting).
Findings
Between Oct 7, 2015, and Sept 19, 2018, 1280 patients were enrolled after complete resection. 1269 received adjuvant chemotherapy, of whom 1005 patients were eligible for randomisation to atezolizumab (n=507) or best supportive care (n=498); 495 in each group received treatment. After a median follow-up of 32·2 months (IQR 27·4-38·3) in the stage II-IIIA population, atezolizumab treatment improved disease-free survival compared with best supportive care in patients in the stage II-IIIA population whose tumours expressed PD-L1 on 1% or more of tumour cells (HR 0·66; 95% CI 0·50-0·88; p=0·0039) and in all patients in the stage II-IIIA population (0·79; 0·64-0·96; p=0·020). In the ITT population, HR for disease-free survival was 0·81 (0·67-0·99; p=0·040). Atezolizumab-related grade 3 and 4 adverse events occurred in 53 (11%) of 495 patients and grade 5 events in four patients (1%).
Interpretation
IMpower010 showed a disease-free survival benefit with atezolizumab versus best supportive care after adjuvant chemotherapy in patients with resected stage II-IIIA NSCLC, with pronounced benefit in the subgroup whose tumours expressed PD-L1 on 1% or more of tumour cells, and no new safety signals. Atezolizumab after adjuvant chemotherapy offers a promising treatment option for patients with resected early-stage NSCLC.
Funding
F Hoffmann-La Roche and Genentech.
Related Questions
How do you decide between neoadjuvant or perioperative chemoimmunotherapy, as per Checkmate 816 or KEYNOTE-671, for early-stage NSCLC?
All of us caring for patients with a lung cancer diagnosis face a very challenging “now what” scenario following publications of many studies demonstrating benefits of a neoadjuvant and/or perioperative approach for the treatment of patients with resectable NSCLC with already 2 FDA approvals of the ...
Would you consider omission of PORT for node+ NSCLC with a positive margin in the setting of a high tumor PD-L1 score and plans for immunotherapy?
For gross positive margins (R2), no, adjuvant chemoRT followed by consolidation immunotherapy. For R1, SOC would still say PORT and adjuvant systemic therapy. But let's try to tease it out in a more nuanced way from available data. First PD-L1 high is certainly a check in the plus column for a clini...
Would you offer any additional adjuvant therapy after platinum based chemotherapy for patients with resected PD-L1 positive Stage II-III lung adenocarcinoma with EGFR exon 20 insertions?
At this time, I would likely offer adjuvant immunotherapy as in KEYNOTE-091 NCT02504372 (pembrolizumab) or IMpower010 (atezolizumab). Though EGFR ex20ins mutations occur mainly in non-smoking patients with NSCLC, a population that tends to benefit less from immunotherapy, there is little data to sug...
What adjuvant therapy would you offer following adjuvant chemotherapy for a patient with Stage III lung adenocarcinoma with an atypical EGFR mutation such as EGFR L861R?
Mutations at position 861 (most commonly L861Q) have been described, occurring in approximately 2% of all EGFR-mutant patients [Mitsudomi and Yatabe, PMID 19922469]. These mutations are considered partially sensitizing to afatinib based on a post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung ...
Would you consider adjuvant immune checkpoint inhibitor therapy for non-small cell lung cancer patients with residual disease after neoadjuvant chemoradiation and surgical resection?
Prior radiation was an exclusion criteria for adjuvant atezolizumab in IMpower010. Also, neoadjuvant chemotherapy was not permitted and patients only received 4 cycles of adjuvant cisplatin based chemotherapy prior to atezolizumab. So this would be outside the scope of the trial. That being said, I ...
Are there any situations where you would consider neoadjuvant chemoradiation as opposed to chemoimmunotherapy for patients with resectable NSCLC prior to surgical resection?
For most of the last 2 decades, there has been a raging debate about the best perioperative approach for the management of patients with high-risk resectable NSCLC, such as patients for example, with preop documented nodal disease. Clinical studies have not been able to settle the key questions whet...
How do you choose between neoadjuvant and adjuvant chemo-immunotherapy for patients with resectable stage II-IIIA NSCLC?
The billion dollar question. For patients with resectable stage II-IIIA NSCLC, how do you choose between neoadjuvant and adjuvant chemo-immunotherapy in light of the recent FDA approval of the CheckMate-816 regimen? Of course, this approval quickly followed in the footsteps of the FDA approval of at...
Should IMPower010 results be extrapolated to superior sulcus tumors treated with chemoradiation and surgery?
No. Patients with superior sulcus NSCLC, for whom the standard of care is preoperative chemotherapy and radiation therapy followed by surgical resection, would all have been ineligible for IMpower010, which used chemotherapy +/- Atezolizumab in the purely adjuvant therapy setting. Therefore, the res...
Would you administer postoperative adjuvant atezolizumab or chemotherapy for patients with locally advanced NSCLC and pathological residual disease following neoadjuvant nivolumab/chemotherapy and surgical resection?
This is an excellent question. First, I would encourage all to check out some wonderful thoughts by Dr. @Dr. First Last in two separate questions regarding perioperative NSCLC here and here. There are additional insights in this question as well. As of now, we do not have firm data on what, if any, ...
What are best practices for engaging with multidisciplinary colleagues to ensure patients with earlier stage NSCLC are being appropriately considered for novel adjuvant therapies?
Multi-disciplinary care for most patients with Stage 1-3 NSCLC is standard of care. (Perhaps also for metastatic NSCLC or SCLC, but that’s a whole other story!) The discussion regarding treatment planning should occur before, and not after, the patient’s local treatment has been initiated. Questions...
Would you consider SBRT and adjuvant therapy for a 4cm, node-negative, non-oncogene driven, NSCLC not amenable to surgical resection?
Ultimately, currently open clinical trials will address this question (i.e., SWOG-S1914, NCT04214262). In the absence of this, there have been several questions here on this topic ranging from the possible role for adjuvant chemotherapy, incorporating ctDNA testing, and how to follow these patients ...
How would use of adjuvant atezolizumab for PDL1+ NSCLC potentially impact your treatment choice at recurrence?
Certainly pattern of relapse is important, and those with local or locoregional recurrences could be treated with definitive intent SBRT, surgery, or concurrent chemotherapy and radiation for mediastinal recurrence. For those with recurrent not amenable to local therapy, this is a challenging questi...
Should 1 year of atezolizumab be the standard of care for stage II-IIIA resected PDL1+ NSCLC?
The gold standard endpoint for trials for patients with curable NSCLC has been overall survival. If a therapy delays disease recurrence, but does not impact survival, one could argue that it should not be used in the adjuvant setting and used at the time of recurrence and similar benefits and overal...
Would you extrapolate IMPower010 data to offer adjuvant atezolizumab to a patient with N2 PDL1-high (>50%) NSCLC who had been treated with induction chemotherapy followed by definitive R0 resection after partial response?
As outlined by Dr. @Dr. First Last, IMpower010 did not enroll patients who had received neoadjuvant chemotherapy and I fully agree that neoadjuvant chemotherapy + immunotherapy trial would be appealing in patients with N2 disease. Especially, since treatment of these patients is controversial and ch...
What is your recommended adjuvant approach to resected NSCLC with both PD-L1>1% and EGFR mutation?
IMpower010 included patients with EGFR mutations, which made up about 10% of the patients enrolled in the trial. In the subgroup analysis of EGFR patients whose tumors expressed PDL1 ≥1%, the HR of 0.57 favored atezolizumab, but had a wide confidence interval (95% CI, 0.26-1.24). Other studies of im...
For which patients with resected NSCLC will you offer adjuvant atezolizumab after completion of cisplatin-based adjuvant chemotherapy?
The initial results of IMpower010 were presented by Dr. @Dr. First Last at ASCO 2021. This study demonstrated that adjuvant atezolizumab following surgical resection and adjuvant platinum based chemotherapy improved disease free survival in stage II-IIIA NSCLC patients with tumors with PDL1 expressi...
Do you perform PDL1 and molecular testing for patients with stages I-III NSCLC?
Do you order PDL1 and molecular testing for patients with stages I-III NSCLC?When I answered this question about two years ago, I said no, primarily because there was no Level 1 efficacy data to support an improvement in outcomes for these patients. This has since changed... although in some ways, n...